Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera

The globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern Omicron (B.1.1.529) has a large number of mutations, especially in the spike protein, indicating that recognition by neutralizing antibodies may be compromised. We tested Wuhan (Wuhan-Hu-1 refere...

Descripción completa

Detalles Bibliográficos
Autores principales: Muik, Alexander, Lui, Bonny Gaby, Wallisch, Ann-Kathrin, Bacher, Maren, Mühl, Julia, Reinholz, Jonas, Ozhelvaci, Orkun, Beckmann, Nina, Güimil Garcia, Ramón de la Caridad, Poran, Asaf, Shpyro, Svetlana, Finlayson, Andrew, Cai, Hui, Yang, Qi, Swanson, Kena A., Türeci, Özlem, Şahin, Uğur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9836206/
https://www.ncbi.nlm.nih.gov/pubmed/35040667
http://dx.doi.org/10.1126/science.abn7591
Descripción
Sumario:The globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern Omicron (B.1.1.529) has a large number of mutations, especially in the spike protein, indicating that recognition by neutralizing antibodies may be compromised. We tested Wuhan (Wuhan-Hu-1 reference strain), Beta (B.1.351), Delta (B.1.617.2), or Omicron pseudoviruses with sera of 51 participants who received two or three doses of the messenger RNA (mRNA)–based COVID-19 vaccine BNT162b2. After two doses, Omicron-neutralizing titers were reduced >22-fold compared with Wuhan-neutralizing titers. One month after the third vaccine dose, Omicron-neutralizing titers were increased 23-fold relative to their levels after two doses and were similar to levels of Wuhan-neutralizing titers after two doses. The requirement of a third vaccine dose to effectively neutralize Omicron was confirmed with sera from a subset of participants using live SARS-CoV-2. These data suggest that three doses of the mRNA vaccine BNT162b2 may protect against Omicron-mediated COVID-19.

Ejemplares similares